Follow
T cell infiltration tumor
T cells are a type of immune cell involved in identifying and killing cancer cells. T cells that infiltrate tumors, known as tumor infiltrating T cells (TILs), are a positive prognostic factor for cancer patients. Cellular therapies remove TILs from a patient, expand them in a laboratory, and administer them back to the patient.
What's Popular in T cell infiltration tumor
-
FEB 29, 2024Immunology
Myeloid cells are a population of cells classified to denote a specific lineage. “Myeloid” specifically refe ...Written By: Brian G. MorrealeFEB 22, 2024Immunology
The US Food and Drug Administration (FDA) recently approved a tumor-infiltrating lymphocyte (TIL) therapy referred to as ...Written By: Brian G. MorrealeFEB 15, 2024Immunology
Scientists have dedicated their lives to finding a cure for cancer. America became a science hub for cancer research, pa ...Written By: Brian G. MorrealeDEC 25, 2023Cancer
Regulatory T cells, Tregs for short, represent a divisive type of immune cell that can elicit beneficial but also harmfu ...Written By: Katie KokolusNOV 30, 2023Immunology
Engineered immune cells have been the topic of investigation for the last few decades. Just 11 years ago a child was tre ...Written By: Brian G. Morreale
FEB 29, 2024
Immunology
Myeloid cells are a population of cells classified to denote a specific lineage. “Myeloid” specifically refe
...
Written By:
Brian G. Morreale
FEB 22, 2024
Immunology
The US Food and Drug Administration (FDA) recently approved a tumor-infiltrating lymphocyte (TIL) therapy referred to as
...
Written By:
Brian G. Morreale
FEB 15, 2024
Immunology
Scientists have dedicated their lives to finding a cure for cancer. America became a science hub for cancer research, pa
...
Written By:
Brian G. Morreale
DEC 25, 2023
Cancer
Regulatory T cells, Tregs for short, represent a divisive type of immune cell that can elicit beneficial but also harmfu
...
Written By:
Katie Kokolus
NOV 30, 2023
Immunology
Engineered immune cells have been the topic of investigation for the last few decades. Just 11 years ago a child was tre
...
Written By:
Brian G. Morreale
SEP 08, 2023
Drug Discovery & Development
Groundbreaking clinical trial that unveils the power of neoadjuvant anti-PD-1 therapy in head and neck squamous cell car
...
Written By:
Amielle Moreno
AUG 16, 2023
Immunology
Glioblastoma is a fast-growing and aggressive brain tumor. As one of the most common malignant brain tumors, life expect
...
Written By:
Brian G. Morreale
MAY 09, 2023
Immunology
Cancer immunotherapy constantly evolves, and discoveries and treatments targeting more aggressive cancers are published
...
Written By:
Brian G. Morreale
APR 17, 2023
Immunology
Bacteria can live in a lot of unusual places, even in tumors in the human body. Scientists have now taken advantage of t
...
Written By:
Carmen Leitch
-
MAR 28, 2024 | 8:00 AM
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...SEP 28, 2023 | 7:00 AM
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...DEC 07, 2022 | 9:00 AM
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...Speaker: Jessica Hess , Rukia Henry , Ernesto Goulart , Ameet Chimote, PhDSponsored By: Thermo Fisher Scientific/GibcoNOV 04, 2021 | 8:00 AM
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
MAR 28, 2024 | 8:00 AM
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
SEP 28, 2023 | 7:00 AM
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
DEC 07, 2022 | 9:00 AM
Date: December 07, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Join us for an exciting live panel webinar, as we celebrate the 60th anniversary of Gibco Cell Culture. The panelists...
Speaker:
Jessica Hess
, Rukia Henry
, Ernesto Goulart
, Ameet Chimote, PhD
Sponsored By: Thermo Fisher Scientific/Gibco
NOV 04, 2021 | 8:00 AM
Date: November 4, 2021 Time: 8:00am (PDT), 11:00am (EDT) The promise of tissue clearing techniques in combination with 3D-immunofluorescence (IF) microscopy is revolutionary. Complex biologi...
OCT 07, 2021 | 11:55 PM
Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the defini...
AUG 26, 2021 | 7:00 AM
Date: August 26, 2021 Time: 7:00am (PDT), 10:00am (EDT) Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with rising incidence and a remarkable resistance to current therapies. In t...
JUL 22, 2021 | 12:00 PM
T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral...
JUN 02, 2021 | 1:30 PM
Hypoxia is pervasive across human cancer and its association with poor outcomes and aggressive malignant phenotypes has been increasingly appreciated. Previously, we and others described how...
JUN 02, 2021 | 12:00 AM
Progress developing immune-based treatments to treat the highly lethal pancreatic ductal adenocarcinoma (PDA) has lagged behind other cancer types. This may be due, in part, to a fibroinflam...
-
OCT 19, 2022 | 5:30 AM PDT
Labroots announces the 2022 Coronavirus Virtual Event Series. A novel coronavirus emerged in China in 2019; it has since been dubbed COVID-19....OCT 06, 2021 | 5:30 AM PDT
Labroots and the Cancer Research and Oncology Planning Committee are pleased to announce the 9th Annual Event in the Cancer Research & Oncology Week Virtual Event Series!...OCT 04, 2021 | 8:00 AM PDT
To SBI2 members and sponsors, On behalf of the Society of Biomolecular Imaging and Informatics Board of Directors, I am pleased to announce the 8th annual High Content conference which will...SEP 14, 2021 | 12:00 AM PDT
Europe - 9:00 AM Central European Summer Time Americas - 9:00 AM Central Daylight Time Asia-Pacific - 9:00 AM Beijing Standard Time (*September 15) ADVANCING SCIENCE: A VIRTUAL IMMUNOLOGY CO...JUL 22, 2021 | 5:00 AM PDT
Gene and cell engineering advances have influenced almost all branches of life sciences. From the lab to the clinic, innovative gene synthesis technologies and gene editing tools have transf...
OCT 19, 2022
| 5:30 AM PDT
Labroots announces the 2022 Coronavirus Virtual Event Series. A novel coronavirus emerged in China in 2019; it has since been dubbed COVID-19....
OCT 06, 2021
| 5:30 AM PDT
Labroots and the Cancer Research and Oncology Planning Committee are pleased to announce the 9th Annual Event in the Cancer Research & Oncology Week Virtual Event Series!...
OCT 04, 2021
| 8:00 AM PDT
To SBI2 members and sponsors, On behalf of the Society of Biomolecular Imaging and Informatics Board of Directors, I am pleased to announce the 8th annual High Content conference which will...
SEP 14, 2021
| 12:00 AM PDT
Europe - 9:00 AM Central European Summer Time Americas - 9:00 AM Central Daylight Time Asia-Pacific - 9:00 AM Beijing Standard Time (*September 15) ADVANCING SCIENCE: A VIRTUAL IMMUNOLOGY CO...
JUL 22, 2021
| 5:00 AM PDT
Gene and cell engineering advances have influenced almost all branches of life sciences. From the lab to the clinic, innovative gene synthesis technologies and gene editing tools have transf...
JUN 02, 2021
| 5:30 AM PDT
Labroots is pleased to announce the inauguration of the Immuno-Oncology Virtual Event Series taking place on June 2, 2021. Immuno-oncology is considered by some to be...
Roche and Labroots are pleased to announce the first-ever global DISCOVERY user symposium. This two-day event will take place November 12-13, 2020 and will focus on advancements in tissue res...
FEB 24, 2021
| 5:30 AM PST
Labroots and the Drug Discovery planning committee are pleased to announce the 4th annual event in the Drug Discovery & Development Virtual Event Series....
OCT 07, 2020
| 5:30 AM PDT
LabRoots and the Cancer Research and Oncology Planning Committee are pleased to announce the 8th Annual Event in the Cancer Research & Oncology Week Virtual Event Series!...